Introduction
============

Bladder cancer is one of the most common malignant neoplasms in the world. It is the sixth leading cause of new cancer cases and ninth leading cause of cancer-related mortality worldwide.[@b1-ott-8-3401] According to data from 2012 provided by American Cancer Society, the incidence of bladder cancer in men and women was 5.3/100,000 and 1.5/100,000, respectively, in less developed countries. In developed countries, the bladder cancer incidence in men (16.9/100,000) was four times as high as that in women (3.7/100,000).[@b1-ott-8-3401] On average, 75% of patients with bladder cancer are diagnosed with nonmuscle invasive tumors limited to the mucosa or lamina propria. For nonmuscle invasive bladder tumors, the probability of recurrence and progression after transurethral resection of bladder tumor (TURBT) at 1 year is 15%--70% and 7%--40%, respectively.[@b2-ott-8-3401],[@b3-ott-8-3401] Lymphovascular invasion (LVI) is a pathological feature that has been receiving attention as the presence of tumor cells within the lumen of the blood and/or lymphatics; the process of which leads to circulating tumor cells. Several prior studies have evaluated that patients with muscle-invasive bladder tumors after radical cystectomy (RC) have an LVI incidence of 30%--50%.[@b4-ott-8-3401]--[@b8-ott-8-3401] The prognostic value of LVI in these patients has been previously investigated by others and it showed that it was independently associated with overall and recurrence-free survival (RFS).[@b4-ott-8-3401],[@b6-ott-8-3401],[@b7-ott-8-3401] However, the conclusions referred above are largely limited in muscle invasive tumors treated with RC. It is still debatable that whether LVI in patients with pT1 urothelial carcinoma of bladder after TURBT has a statistically significant impact on prognosis. A retrospective study conducted by Cho et al[@b9-ott-8-3401] revealed that LVI, as an independent prognostic factor in pT1 bladder cancer, was significantly associated with disease recurrence. However, others contradicted this finding, they maintained that LVI in stage T1 tumors was unusual and frequently misdiagnosed on hematoxylin and eosin (H&E) stain; it did not necessarily portend a poor prognosis.[@b10-ott-8-3401] Thus, the purpose of this study is to assess the independent prognostic role of LVI in patients with newly diagnosed pT1 urothelial carcinoma of the bladder.

Patients and methods
====================

Clinical data
-------------

With the approval from the institutional review board of the Second Hospital of Tianjin Medical University, a total of 155 patients newly diagnosed with pT1 bladder cancer who underwent TURBT at our institution from January 2006 to January 2010 were selected retrospectively for the analysis. Clinical and pathological information was retrospectively obtained from patient charts and electronic medical records, including age, sex, tumor size, tumor multiplicity, tumor grade, carcinoma in situ (CIS), and smoking. Tumor size was considered as the greater diameter on microscopic analysis of the surgical specimen.

Our inclusion criteria were 1) TURBT was performed as initial treatment for all patients; 2) evidence of urothelial carcinoma of the bladder; 3) an available pathology report for review; and 4) tumor was pathologically diagnosed as pT1. Individuals were excluded if they met all of the following inclusion criteria: 1) evidence of nonurothelial carcinoma histology; 2) presence of adenocarcinoma, squamous cell carcinoma, or other histological variants; 3) presence of upper tract carcinoma, or distant metastasis (including regional nodal metastasis) at diagnosis. Due to the inaccessible Bacillus Calmette--Guerin in the People's Republic of China, patients received the anthracycline antibiotic chemotherapy drugs such as epirubicin or pirarubicin with an 8-week course. The study population comprised two groups, patients with LVI-positive and LVI-negative at TURBT. We compared those LVI patients with a group of patients who had no evidence of LVI.

Treatments
----------

All patients underwent TURBT that was carried out by all surgeons according to a standard procedure in our study. All visible tumors or suspicious mucosal lesions were resected until the tumor base reached the deep muscle layer and showed perivesical fat transparently. T stage was determined according to the 2002 American Joint Committee on Cancer tumor, node, metastasis (TNM) staging system, and tumor grade was determined using the 2004 World Health Organization grading system. LVI status, defined as the presence of vascular and/or lymphatic invasion, was confirmed by reviewing the pathology reports. If the LVI was not depicted in the pathology report, then it would be reassigned by two independent uropathologists in our institute. LVI was considered present when tumor cells were unequivocally noted within or attached to the wall of a vascular or lymphatic space on H&E-stained sections. The presence of LVI was only assessed on the first TURBT.

Cystoscopy has been suggested to be given during the regular postoperative follow-up at 3-month interval for the first 2 years, biannually for the subsequent 3 years, and annually thereafter according to the US and European guidelines.[@b11-ott-8-3401] The end point was the date of the last visit to our institute. Of course, patients were monitored with physical examinations, routine ultrasonic tests, and urine cytology at each visit. Outcomes of interest were RFS and progression-free survival (PFS). The RFS period was obtained from the date of first surgery to the date of first clinical recurrence (any histopathological staging and/or grading). The PFS period was estimated from the time of first surgery to the date of disease developed to higher histopathological staging and/or grading and/or to metastasis. Time of collecting data was the end point for patients without recurrence and progression.

Statistical analysis
--------------------

Chi-square test was used to compare the association between LVI and other clinicopathological characteristics. We examined the impact of LVI on disease recurrence and progression. Univariable and multivariable Cox proportional hazards analysis models were used to analyze the prognostic significance of the clinical and pathological variables for RFS and PFS. Kaplan--Meier analysis and the log-rank test were done to calculate RFS and PFS curves and analyzed the significance of differences between survival curves. Statistical software SPSS (IBM Corporation, Armonk, NY, USA) version 20.0 was used for statistical analysis with two-sided *P*\<0.05 considered significant.

Results
=======

The clinicopathological demographics of patients who were newly diagnosed with pT1 urothelial carcinoma of bladder after TURBT with LVI (+) and those with LVI (−) are shown in [Table 1](#t1-ott-8-3401){ref-type="table"}. Among a total of 155 patients, LVI was histologically confirmed in 34 patients (21.9%). Of these tumors, 30 occurred in men and four in women. There were no significant differences between the two groups in terms of age, sex, tumor size, tumor multiplicity, CIS, and smoking. However, high-grade tumors were more common in LVI (+) than in LVI (−) (70.6% versus 30.6%, *P*\<0.001).

The mean (range) follow-up time for the group with LVI was 86.4 (6--114) months and was 78.4 (7--114) months for the controls. During the follow-up, disease recurrence and progression developed in 49 (31.6%) and 20 (12.9%) patients, respectively ([Table 2](#t2-ott-8-3401){ref-type="table"}). Patients with LVI (+) were significantly more likely to recur than those with LVI (−) (50.0% versus 26.4%, *P*=0.009). There was also a trend for patients with LVI (+) to be high in the rates of progression comparing with patients with LVI (−) (20.6% versus 10.7%), but the difference was not statistically significant (*P*=0.130).

We used Cox proportional hazard analysis for further analysis ([Table 3](#t3-ott-8-3401){ref-type="table"}). According to the results of univariate analysis, we found that tumor multiplicity (hazard ratio \[HR\] 1.790, 95% confidence interval \[CI\] 1.019--3.143, *P*=0.043), tumor size (HR 1.971, 95% CI 1.118--3.474, *P*=0.019), smoking (HR 2.282, 95% CI 1.297--4.013, *P*=0.004), and the presence of LVI (HR 2.060, 95% CI 1.142--3.714, *P*=0.016) significantly influenced disease recurrence time. However, in multivariate Cox proportional hazard analysis, only tumor size (HR 1.817, 95% CI 1.014--3.256, *P*=0.045), smoking (HR 2.079, 95% CI 1.172--3.687, *P*=0.012), and the presence of LVI (HR 2.042, 95% CI 1.113--3.746, *P*=0.021) were the independent prognostic factors associated with disease recurrence.

The Kaplan--Meier analysis was used to estimate RFS and PFS stratified by LVI (+) versus LVI (−) in [Figures 1](#f1-ott-8-3401){ref-type="fig"} and [2](#f2-ott-8-3401){ref-type="fig"}. Patients with LVI (+) had shorter mean RFS duration than those with LVI (−) (74.8 versus 90.9 months, *P*=0.014). However, no significant difference was observed between the two groups in terms of PFS (104.7 versus 105.3 months, *P*=0.312).

Discussion
==========

The value of LVI as a criterion to evaluate the severity of urothelial bladder tumors was reported for the first time by McDonald and Thompson.[@b12-ott-8-3401] Evidence on the clinical significance of LVI in bladder cancer is increasing, and a great many recent cystectomy series have strengthened the significance of LVI for urothelial carcinoma of the bladder. Some series indicated that LVI was a significant and independent prognostic factor for disease-specific survival, as well as pathological staging and presence of lymph node metastasis in patients who underwent RC.[@b13-ott-8-3401],[@b14-ott-8-3401] Patients with LVI at RC were significantly more likely to have disease recurrence than those with no evidence of LVI.[@b15-ott-8-3401] Kim et al[@b16-ott-8-3401] conducted a systematic review and meta-analysis including a total of 12,527 patients to assess the association between LVI and prognosis of bladder cancer after RC. The result revealed that LVI was detected in 34.6% in RC specimens and it was a significant predictor for poor survival.

Nonetheless, there are only limited data on the clinical guiding significance of LVI in TURBT specimens in patients with nonmuscle invasive bladder cancer, especially pT1 urothelial carcinoma of bladder. Cho et al,[@b9-ott-8-3401] who performed retrospective analyses of 118 patients reported that LVI, as an independent prognostic factor of progression and metastasis in pT1 bladder cancer, was significantly associated with disease recurrence. The result was consistent with the study conducted by Lopez and Angulo,[@b17-ott-8-3401] in which multivariate analysis revealed that LVI proved to be an independent prognostic factor in TURBT surgical specimens of T1 bladder cancer. However, several previous reports held a contrary opinion, maintaining that LVI did not necessarily portend a poor prognosis in pT1 bladder cancer,[@b10-ott-8-3401] and the presence of LVI in patients with node-negative was not an unfavorable factor of prognosis on multivariate analysis.[@b18-ott-8-3401] They revealed that the pathologic stage was the only independent prognostic factor for survival. This study provided further evidence suggesting that LVI was a pathological variable that might play an important role as a prognostic indicator in patients with newly diagnosed pT1 bladder cancer. Our study showed that the presence of LVI was the independent prognostic factor associated with disease recurrence (HR 2.042, 95% CI 1.113--3.746, *P*=0.021). However, the association between LVI and progression was not statistically significant (*P*=0.130).

Moreover, some studies showed a 10%--25% LVI rate in pT1 bladder cancer cases.[@b17-ott-8-3401],[@b19-ott-8-3401]--[@b21-ott-8-3401] In accordance with previous studies, we found that LVI was detected pathologically in 21.9% of cases in our series. Also, disease recurrence and progression developed in 17 (50.0%) and seven (20.6%) patients within a mean follow-up of 86.4 (6--114) months after TURBT, respectively.

Treatment for nonmuscle invasive bladder cancer with LVI is also under debate. Cho et al considered systemic chemotherapy a reasonable option based on the assumption that undetectable micrometastasis might be present in patients with LVI. While there were no statistically significant differences between patients who did and did not undergo adjuvant systemic chemotherapy in terms of time to disease recurrence, progression, or metastasis.[@b9-ott-8-3401] Its presence in the TURBT specimen had special value, because if LVI was found before RC, then neoadjuvant chemotherapy or early RC might be considered.[@b22-ott-8-3401] In addition to being used to select adjuvant therapy as predictive tools, LVI should be considered for inclusion in the TNM staging system. Despite a growing number of published studies have proved the important role of LVI on the prognosis of bladder cancer, it is not a part of the TNM staging system or treatment guidelines for bladder cancer. In other malignancies such as hepatic[@b23-ott-8-3401] and testicular cancer,[@b24-ott-8-3401] LVI has been added to the TNM staging system in case of underestimating disease staging, so that we can improve the decision-making of disease treatment. Upstaging tumors on the basis of LVI might improve the accuracy of prognosis in bladder cancer, therefore, it is a worthy consideration. Although it is mostly accepted that LVI is an indicator of bladder cancer aggressiveness, on account of difficult identification and questionable reproducibility of LVI in a limited TURBT surgical specimen, controversy on the impact of LVI on staging and therapeutic decision-making still remains. So further studies are still needed to evaluate potential treatment options for nonmuscle invasive bladder cancer with LVI.

Clearly, several limitations of this study need to be considered. First and foremost were its retrospective characteristic and the limited study sample, although all the data were extracted from our medical institution, the possibility of selection bias could not be excluded. In addition, the patients in our study underwent TURBT by multiple surgeons, and specimens were evaluated by different pathologists. In addition, we determined most of LVI cases by H&E staining, not based on immunohistochemical staining such as CD31 or CD34 staining, which might help in identification of LVI.[@b25-ott-8-3401] Due to the misdiagnosis of LVI in H&E-stained specimens, it may have contributed to LVI overestimation. Moreover, we did not control for repeat TURBT on patients with a suspicion of residual tumor in initial TURBT specimens, which could have affected outcomes.[@b26-ott-8-3401]

Conclusion
==========

This study provides further evidence that the presence of LVI in TURBT specimens is significantly associated with an increased risk of disease recurrence and a shorter RFS time in patients with newly diagnosed T1 urothelial carcinoma of the bladder. As an independent prognostic predictor for disease recurrence, patients with LVI should be followed up closely in case of recurrence.
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![Kaplan--Meier curve of the recurrence-free survival rates for the two groups (log-rank test result: 0.014).\
**Abbreviations:** Cum, cumulative; LVI, lymphovascular invasion; RFS, recurrence-free survival.](ott-8-3401Fig1){#f1-ott-8-3401}

![Kaplan--Meier curve of the progression-free survival rates for the two groups (log-rank test result: 0.312).\
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###### 

Clinicopathological demographics on 155 patients with newly diagnosed bladder T1 urothelial carcinoma stratified by LVI

  Variable                                                     Number of patients (%)   Number of LVI (%)   *P*-value       
  ------------------------------------------------------------ ------------------------ ------------------- --------------- ---------
  Age (years)                                                                                                               0.227
   \<65                                                        78 (50.3)                64 (52.9)           14 (41.2)       
   ≥65                                                         77 (49.7)                57 (47.1)           20 (58.8)       
  Sex                                                                                                                       0.376
   Male                                                        129 (83.2)               99 (81.8)           30 (88.2)       
   Female                                                      26 (16.8)                22 (18.2)           4 (11.8)        
  Tumor size[\*](#tfn1-ott-8-3401){ref-type="table-fn"} (cm)                                                                0.969
   \<3                                                         109 (70.3)               85 (70.2)           24 (70.6)       
    ≥3                                                         46 (29.7)                36 (29.8)           10 (29.4)       
  Tumor multiplicity                                                                                                        0.196
   Single                                                      88 (57.8)                72 (59.5)           16 (47.1)       
   Multiple                                                    67 (42.2)                49 (40.5)           18 (52.9)       
  Tumor grade                                                                                                               \<0.001
   Low                                                         94 (60.6)                84 (69.4)           10 (29.4)       
   High                                                        61 (39.4)                37 (30.6)           24 (70.6)       
  Carcinoma in situ                                                                                                         0.321
   Yes                                                         5 (3.2)                  3 (2.4)             2 (6.9)         
   No                                                          150 (96.8)               118 (97.5)          32 (94.1)       
  Smoking history                                                                                                           0.438
   Yes                                                         59 (38.1)                48 (39.7)           11 (32.4)       
   No                                                          96 (61.9)                73 (60.3)           23 (67.6)       
  Intravesical therapy                                                                                                      0.009
   Yes                                                         151 (97.4)               120 (99.2)          31 (91.2)       
   No                                                          4 (2.6)                  1 (0.8)             3 (8.8)         
  Mean follow-up, mo (range)                                                            78.4 (7--114)       86.4 (6--114)   0.115

**Note:**

Largest diameter of tumor resected.

**Abbreviations:** LVI, lymphovascular invasion; mo, months.

###### 

Distribution of the two groups in accordance with recurrence and progression

  Variable               Number of patients   LVI (%)          *P*-value
  ---------------------- -------------------- ---------------- -----------
  Recurrence                                                   0.009
   Yes                   32 (26.4)            17 (50.0)        
   No                    89 (73.6)            17 (50.0)        
  Mean RFS, mo (range)   90.9 (4--114)        74.8 (4--112)    0.014
  Progression                                                  0.130
   Yes                   13 (10.7)            7 (20.6)         
   No                    108 (89.3)           27 (79.4)        
  Mean PFS, mo (range)   105.3 (7--114)       104.7 (6--114)   0.312

**Abbreviations:** LVI, lymphovascular invasion; mo, months; PFS, progression-free survival; RFS, recurrence-free survival.

###### 

Univariable and multivariable analyses according to recurrence

  Factor                 Univariable            Multivariable                          
  ---------------------- ---------------------- --------------- ---------------------- -------
  Age (years)                                                                          
   \<65, ≥65             1.765 (0.987--3.156)   0.055           --                     --
  Sex                                                                                  
   Male, female          2.344 (0.843--6.523)   0.103           --                     --
  Tumor multiplicity                                                                   
   Single, multiple      1.790 (1.019--3.143)   0.043           1.379 (0.761--2.499)   0.289
  Tumor size, cm                                                                       
   \<3, ≥3               1.971 (1.118--3.474)   0.019           1.817 (1.014--3.256)   0.045
  Tumor grade                                   0.101                                  
   Low, high             1.600 (0.912--2.805)                   --                     --
  Carcinoma in situ                                                                    
   Yes, no               1.015 (0.244--4.219)   0.984           --                     --
  LVI                                                                                  
   Yes, no               2.060 (1.142--3.714)   0.016           2.042 (1.113--3.746)   0.021
  Smoking history                                                                      
   Yes, no               2.282 (1.297--4.013)   0.004           2.079 (1.172--3.687)   0.012
  Intravesical therapy                                                                 
   Yes, no               2.185 (0.670--7.121)   0.195           --                     --

**Abbreviations:** CI, confidence interval; HR, hazard ratio; LVI, lymphovascular invasion.
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